Latest medical news: Is ixazomib on the market?

Ixazomib (Ixazomib) is a second-generation proteasome inhibitor (PI) and is also approved by the U.S. Food and Drug Administration (FDA) The first oral PI approved in November 2015, for the treatment of multiple myeloma in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for the treatment of multiple myeloma) in controlling myeloma growth and preventing bone loss. Ixazomib is sold overseas under the trade nameNinlaro.

Ixazomib is a reversible proteasome inhibitor. Ixazomib induces apoptosis in multiple myeloma cells in vitro. Ixazomib demonstrated in vitro cytotoxicity against myeloma cells derived from patients who had relapsed after prior treatment with multiple therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide shows synergistic cytotoxic effects in multiple myeloma cell lines. In vivo, ixazomib showed antitumor activity in a mouse xenograft model of multiple myeloma.

The original drug of Ixazomib has been launched in China, sold under the name of Ixazomib Citrate Capsules, and is included in Class B medical insurance. The price of common capsule preparations may be more than 10,000 yuan per box, which is relatively expensive. The price of the original drug of ixazomib sold overseas is more than 10,000 U.S. dollars per box (the price may fluctuate due to the exchange rate). Ixazomib Generic drugs are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 4mg*3 tablets produced by a Laos pharmaceutical factory may be less than 1,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.